Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B‐cell lymphoma
Sign Up to like & getrecommendations! Published in 2019 at "American Journal of Hematology"
DOI: 10.1002/ajh.25659
Abstract: This phase 1b/2, multicenter, open‐label study evaluated ibrutinib plus durvalumab in relapsed/refractory follicular lymphoma (FL) or diffuse large B‐cell lymphoma (DLBCL). Patients were treated with once‐daily ibrutinib 560 mg plus durvalumab 10 mg/kg every 2 weeks in… read more here.
Keywords: relapsed refractory; lymphoma; dlbcl; refractory follicular ... See more keywords
Axicabtagene ciloleucel for the treatment of relapsed or refractory follicular lymphoma
Sign Up to like & getrecommendations! Published in 2022 at "Expert Review of Anticancer Therapy"
DOI: 10.1080/14737140.2022.2096009
Abstract: ABSTRACT Introduction Axicabtagene ciloleucel is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy that was recently approved for relapsed or refractory follicular lymphoma following progression on two or more lines of therapy including an… read more here.
Keywords: axicabtagene; relapsed refractory; follicular lymphoma; axicabtagene ciloleucel ... See more keywords
Real‐life efficacy and safety of idelalisib in 55 double‐refractory follicular lymphoma patients
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Haematology"
DOI: 10.1111/bjh.18426
Abstract: Idelalisib, a reversible inhibitor of PI3Kδ (phosphoinositide‐3 kinase delta), showed remarkable activity in the phase II DELTA trial, leading to its approval by the European Medicines Agency (EMA) in patients with relapsed/refractory (R/R) follicular lymphoma… read more here.
Keywords: real life; idelalisib; follicular lymphoma; life ... See more keywords
Safety and activity of pembrolizumab in combination with rituximab in relapsed or refractory follicular lymphoma
Sign Up to like & getrecommendations! Published in 2022 at "Blood Advances"
DOI: 10.1182/bloodadvances.2021006240
Abstract: Key Points Combination therapy with pembrolizumab and rituximab was well tolerated in patients with relapsed/refractory follicular lymphoma. In this single-arm, phase 2 study, the overall response rate was 67%, with 50% complete response and median… read more here.
Keywords: refractory follicular; relapsed refractory; combination; follicular lymphoma ... See more keywords
Management of psoriasis-like rash associated with idelalisib monotherapy in a patient with refractory follicular lymphoma: a case report
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Medical Case Reports"
DOI: 10.1186/s13256-020-2344-9
Abstract: Background Follicular lymphoma is an indolent non-Hodgkin lymphoma that is most commonly diagnosed in elderly individuals. The majority of patients with follicular lymphoma present with advanced disease. Despite the recent advances in treatment, there remains… read more here.
Keywords: lymphoma; refractory follicular; treatment; follicular lymphoma ... See more keywords
Targeted Treatment of Relapsed or Refractory Follicular Lymphoma: Focus on the Therapeutic Potential of Mosunetuzumab
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Management and Research"
DOI: 10.2147/cmar.s381493
Abstract: Abstract Follicular lymphoma is the most common indolent non-Hodgkin’s lymphoma, and because of the incurable nature of this disorder, new therapies are constantly needed. The recently approved T-cell-dependent bispecific antibody mosunetuzumab showed promising results and… read more here.
Keywords: lymphoma; relapsed refractory; mosunetuzumab; follicular lymphoma ... See more keywords